Niki BioSolutions Subsidiary Signs Genotyping Agreement with Charter Research
1 report, 1 independent
Updated Oct 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
DiamiR Biosciences, a subsidiary of Niki BioSolutions, signed an agreement with Charter Research to perform apolipoprotein E (APOE) genotyping. The service utilizes a testing platform that is accredited by the College of American Pathologists and approved by the New York State Clinical Laboratory Evaluation Program.
From manilatimes.net
Why it matters
The agreement allows Charter Research, a multi-site clinical research organization, to integrate validated genotyping results into its trial operations. APOE status is a genetic risk factor increasingly used to inform eligibility and risk stratification in neurodegeneration trials.
From manilatimes.net
Who's involved
- College of American PathologistsOrganization whose accreditation standards are used for the testing platform
- GaithersburgCity where a laboratory associated with the College of American Pathologists is located
Keep exploring
The entities involved
-
College of American Pathologists
organization
Nothing else this week.